Blueprint Medicines

Blueprint Medicines Corp. is a precision therapy company. It focuses on medicines to improve the lives of patients with genomically defined cancers, rare diseases, blood disorders, and cancer immunotherapy. The company was founded by Chris Varma, Nicholas B. Lydon, Brian Druker, and Alexis Borisy on October 14, 2008 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Blueprint Medicines exceeds revenue expectations, eyes growth opportunities in 2023

Blueprint Medicines delivered strong financial results and outlined growth strategies for 2023, driven by AYVAKIT's performance.
The company faces uncertainties around label negotiation but benefits from strong market access and proactive market expansion efforts.
Opportunities lie in upcoming data presentations, CDK2 program updates, and capturing additional market share in the ISM segment.

Blueprint Medicines reports strong Q1 performance and growth opportunities

Blueprint Medicines showcased strong financial performance, a robust growth strategy, and promising pipeline advancements during the Q1 earnings call. While facing challenges in managing expenses and differentiating sales, the company is well-positioned to capitalize on opportunities in driving AYVAKYT sales and educating providers on SM treatment urgency.

Blueprint Medicines reports strong Q2 results and eyes market expansion

Blueprint Medicines demonstrated solid financial performance and positive market reception for AYVAKIT and BLU-222.
While facing challenges in operational execution and market competition, the company has opportunities for growth through portfolio expansion and market diversification.
Overall, Blueprint Medicines is well-positioned to capitalize on the success of AYVAKIT and the potential of BLU-222 in driving future growth and innovation.

Blueprint Medicines excels in Q3, eyes sustainable growth in 2024

Blueprint Medicines delivered strong Q3 results with a focus on sustainable revenue growth and pipeline advancement.
The company's strengths lie in AYVAKIT's market adoption, high patient retention rates, and promising pipeline assets.
Challenges include managing operating expenses, decreasing cash burn, and expanding market penetration for AYVAKIT.
Opportunities exist in developing new assets, presenting upcoming data, and achieving significant growth in 2024.

Blueprint Medicines reports robust 2023 performance and targets $2B peak sales

Blueprint Medicines' strong 2023 performance with AYVAKIT driving revenue growth sets the stage for continued success in 2024, aiming for peak sales exceeding $2 billion.
Strategic focus on expanding market presence, advancing pipeline assets, and maintaining financial discipline positions the company for sustained growth and profitability.
Opportunities lie in maximizing AYVAKIT's market potential, leveraging BLU-808 in inflammatory disorders, and exploring strategic growth avenues in cancer treatment.

Blueprint Medicines reports robust Q1 earnings, eyes strategic partnerships

Blueprint Medicines' strong financial performance, focus on sustainable growth, and strategic expansion into new therapeutic areas position the company for long-term success. Addressing challenges in physician adoption and patient prescription rates while leveraging growth opportunities in strategic partnerships and compound expansion will be crucial for future growth.

Blueprint Medicines excels in Q3 with robust AYVAKIT sales

Blueprint Medicines delivered strong revenue growth driven by AYVAKIT sales, showcasing high compliance and demand. With a focus on long-term growth and financial stability, the company aims to expand its impact with BLU-808 and maintain strong capital allocation priorities.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Blueprint Medicines Corp. is a precision therapy company, which engages in the invention of medicines for people with cancer and blood disorders. The company was founded by Chris Varma, Nicholas B. Lydon, Brian Druker, and Alexis Borisy on October 14, 2008 and is headquartered in Cambridge, MA.

-- Breadth of pipeline featured in multiple early clinical data presentations, reflecting diversity of fundamental growth drivers across development programs -- CAMBRIDGE, Mass. , June 3, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC) today announced clinical data for multiple programs across its precision therapy portfolio at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.

Blueprint Medicines Highlights Clinical Progress Across Precision Oncology Pipeline at 2023 ASCO Annual Meeting

-- First and only treatment approved by FDA for indolent SM -- CAMBRIDGE, Mass. , May 23, 2023  /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC) today announced that NEJM Evidence, a journal from The New England Journal of Medicine Group, has published detailed results from the PIONEER trial of AYVAKIT® (avapritinib) in patients with indolent systemic mastocytosis (ISM).

NEJM Evidence Publishes Results from Registrational PIONEER Trial Demonstrating Significant Clinical Benefits of AYVAKIT® (avapritinib) in Patients with Indolent Systemic Mastocytosis

-- For the first time, patients with indolent SM have a medicine that treats the primary disease driver and is proven to provide broad and durable symptom relief -- -- Approval based on the positive PIONEER trial, in which once-daily AYVAKIT achieved significant improvements in disease symptoms and measures of mast cell burden, with a safety profile that compared favorably to placebo -- -- Blueprint Medicines to host investor conference call and webcast today at 4:30 p.m. ET -- CAMBRIDGE, Mass.

FDA Approves AYVAKIT® (avapritinib) as the First and Only Treatment for Indolent Systemic Mastocytosis

Blueprint Medicines focuses on developing precision therapies for genomically defined cancers and blood disorders, with two approved drugs and multiple ongoing programs. The company's stock has risen by 25% since the previous analysis, supported by strong financials and promising Phase 2 trial results for avapritinib in treating ISM.

Blueprint Is Well-Positioned To Capitalize On ISM Market (Maintain 'Buy')

Blueprint Medicines (BPMC) announces better-than-expected results for first-quarter 2023 as it beats estimates for both earnings and revenues. Stock surges 13% following the news.

Blueprint's (BPMC) Q1 Earnings & Sales Top Estimates, View Up

Blueprint Medicines Corporation (NASDAQ:BPMC ) Q1 2023 Earnings Conference Call May 4, 2023 8:00 AM ET Company Participants Jenna Cohen - Senior Director and Head, Investor Relations Kate Haviland - Chief Executive Officer Philina Lee - Chief Commercial Officer Becker Hewes - Chief Medical Officer Mike Landsittel - Chief Financial Officer Fouad Namouni - President, Research & Development Christina Rossi - Chief Operating Officer Conference Call Participants Reni Benjamin - JMP Securities Brad Canino - Stifel Ernie Rodriguez - Cowen and Company Dane Leone - Raymond James Eun Yang - Jefferies Matthew Biegler - Oppenheimer Ami Fadia - Needham & Company Andrew Berens - SVB Securities David Lebowitz - Citi Zhiqiang Shu - Berenberg Capital Operator Good morning. My name is Kelly.

Blueprint Medicines Corporation (BPMC) Q1 2023 Earnings Call Transcript

-- Achieved $39.1 million in AYVAKIT®/AYVAKYT® (avapritinib) net product revenues and $63.3 million in total revenues in the first quarter of 2023 -- -- Raising 2023 AYVAKIT net product revenue guidance to $135 million to $145 million for advanced SM and GIST, excluding additional revenue associated with anticipated U.S. FDA approval for indolent SM -- -- FDA target action date for AYVAKIT supplemental new drug application for indolent SM is May 22, 2023 --   CAMBRIDGE, Mass. , May 4, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today reported financial results and provided a business update for the first quarter ended March 31, 2023.

Blueprint Medicines Reports First Quarter 2023 Results

Blueprint Medicines (BPMC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Blueprint Medicines (BPMC) to Report a Decline in Earnings: What to Look Out for

CAMBRIDGE, Mass. , April 26, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced the acceptance of clinical abstracts for multiple programs across its precision therapy portfolio at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, June 2 to 6.

Blueprint Medicines to Present New Clinical Data Across Broad Precision Therapy Pipeline at 2023 ASCO Annual Meeting

CAMBRIDGE, Mass. , April 20, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live conference call and webcast at 8:00 a.m.

Blueprint Medicines to Report First Quarter 2023 Financial Results on Thursday, May 4, 2023

CAMBRIDGE, Mass. , March 28, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that the U.S. Food and Drug Administration (FDA) has lifted a partial clinical hold on the Phase 1/2 VELA trial of BLU-222.

Blueprint Medicines Announces Lift of Partial Clinical Hold on Phase 1/2 VELA Trial of BLU-222

Blueprint Medicines' avapritinib demonstrated significant improvements in patient-reported symptoms and disease burden in indolent systemic mastocytosis (ISM). Avapritinib's safety profile in the trial was well-tolerated, with fewer serious adverse events and minimal discontinuation rates.

Exploring Blueprint's 'Blockbuster Opportunity' In Indolent Systemic Mastocytosis

-- AYVAKIT achieved a statistically significant and clinically meaningful improvement in total symptom score that deepened over time, with improvements shown across all individual symptoms -- -- AYVAKIT achieved a statistically significant and clinically meaningful improvement on the Mastocytosis Quality of Life Questionnaire (MC-QoL) -- -- AYVAKIT had a favorable safety profile compared to placebo, supporting potential for chronic treatment -- -- Blueprint Medicines to host investor webcast tomorrow, February 27, 2023, at 8:00 a.m. ET -- CAMBRIDGE, Mass.

Blueprint Medicines Presents Registrational Data from PIONEER Trial of AYVAKIT® (avapritinib) in Patients with Indolent Systemic Mastocytosis at 2023 AAAAI Annual Meeting

CAMBRIDGE, Mass. , Feb. 23, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced it will regain global commercialization and development rights to GAVRETO® (pralsetinib), excluding Greater China, following a decision by Roche to discontinue the collaboration agreement between the companies for GAVRETO for strategic reasons.

Blueprint Medicines to Regain Global Rights to GAVRETO® (pralsetinib) from Roche

Blueprint Medicines (BPMC) announces better-than-expected financial performance in fourth-quarter and full-year 2022. Stock up in the aftermarket hours, following the news release.

Blueprint's (BPMC) Q4 Earnings & Sales Top Estimates, Stock Up

Blueprint Medicines Corporation (NASDAQ:BPMC ) Q4 2022 Earnings Conference Call February 16, 2023 8:00 AM ET Company Participants Jenna Cohen - Senior Director and Head of Investor Relations Kate Haviland - Chief Executive Officer Philina Lee - Chief Commercial Officer Christy Rossi - Chief Operating Officer Mike Landsittel - Chief Financial Officer Fouad Namouni - President of Research and Development Becker Hewes - MD, Chief Medical Officer Conference Call Participants Dane Leone - Raymond James Ernie Rodriguez - Cowen and Co Brad Canino - Stifel Eun Yang - Jefferies Derek Archila - Wells Fargo Michael Ulz - Morgan Stanley Reni Benjamin - JMP Securities Joe Beatty - Baird Peter Lawson - Barclays David Lebowitz - Citi Zhi Shu - Berenberg Ami Fadia - Needham Matt Biegler - Oppenheimer Nicole Gabreski - Piper Sandler Operator Good morning, and welcome to the Blueprint Medicines Conference Call. At this time, all participants are in listen-only-mode.

Blueprint Medicines Corporation (BPMC) Q4 2022 Earnings Call Transcript

-- Achieved $204.0 million in total revenues in 2022, including $111.0 million in AYVAKIT®/AYVAKYT® (avapritinib) net product revenues -- -- Continued progress toward regulatory approvals of AYVAKIT/AYVAKYT for indolent systemic mastocytosis, with FDA granting priority review of a supplemental new drug application and EMA validating a type II variation marketing authorization application -- -- Positive data from PIONEER trial of AYVAKIT in indolent systemic mastocytosis to be presented at the AAAAI Annual Meeting -- CAMBRIDGE, Mass. , Feb. 16, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today reported financial results and provided a business update for the fourth quarter and full year ended December 31, 2022.

Blueprint Medicines Reports Fourth Quarter and Full Year 2022 Results

Blueprint's (BPMC) early- to mid-stage study for the treatment of patients with CDK2-vulnerable cancers put on partial clinical hold by the FDA.

Blueprint's (BPMC) Cancer Study Put on Partial Hold by FDA

CAMBRIDGE, Mass. , Feb. 10, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that the U.S. Food and Drug Administration (FDA) verbally informed the company on February 8, 2023 that it has placed a partial clinical hold on the Phase 1/2 VELA trial of BLU-222 due to visual adverse events (AEs) observed in a limited number of patients.

Blueprint Medicines Announces Partial Clinical Hold for Phase 1/2 VELA Trial of BLU-222

CAMBRIDGE, Mass. , Feb. 9, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live conference call and webcast at 8:00 a.m.

Blueprint Medicines to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, February 16, 2023

Blueprint Medicines (BPMC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Blueprint Medicines (BPMC) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

-- Significant scientific and clinical presence, including 10 presentations, underscores breadth and depth of SM leadership -- -- Blueprint Medicines to host investor conference call and webcast on Monday, February 27, 2023 -- CAMBRIDGE, Mass. , Feb. 3, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced plans to present detailed results from the registrational PIONEER trial of AYVAKIT® (avapritinib) in indolent systemic mastocytosis (SM) at the 2023 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Meeting, February 24 to 27 in San Antonio.

Blueprint Medicines to Present Positive Data from PIONEER Trial of AYVAKIT® (avapritinib) in Indolent Systemic Mastocytosis at 2023 AAAAI Annual Meeting

The average of price targets set by Wall Street analysts indicates a potential upside of 61.4% in Blueprint Medicines (BPMC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Can Blueprint Medicines (BPMC) Climb 61.38% to Reach the Level Wall Street Analysts Expect?

The FDA accepts and grants priority review to Blueprint Medicines' (BPMC) sNDA for the label expansion of Aykavit for indolent systemic mastocytosis.

Blueprint Medicines' (BPMC) Aykavit sNDA Gets FDA Priority Tag

-- FDA grants priority review and sets PDUFA action date of May 22, 2023 -- CAMBRIDGE, Mass. , Jan. 23, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's supplemental new drug application for AYVAKIT® (avapritinib) for the treatment of adults with indolent systemic mastocytosis (SM).

Blueprint Medicines Announces FDA Acceptance of Supplemental New Drug Application for AYVAKIT® (avapritinib) for the Treatment of Indolent Systemic Mastocytosis

News for Blueprint Medicines Stock (BPMC)